

**Clinical Policy: Tetrabenazine (Xenazine)**

Reference Number: CP.PHAR.92

Effective Date: 12.01.11

Last Review Date: 05.23

Line of Business: Commercial, HIM, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**Description**

Tetrabenazine (Xenazine<sup>®</sup>) is a vesicular monoamine transporter 2 (VMAT) inhibitor.

**FDA Approved Indication(s)**

Xenazine is indicated for the treatment of chorea associated with Huntington's disease.

**Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Xenazine is **medically necessary** when the following criteria are met:

**I. Initial Approval Criteria****A. Chorea Associated with Huntington Disease (must meet all):**

1. Diagnosis of chorea associated with Huntington disease;
2. Prescribed by or in consultation with a neurologist;
3. Age  $\geq$  18 years;
4. Targeted mutation analysis demonstrates a cytosine-adenine-guanine (CAG) trinucleotide expansion of  $\geq$  36 repeats in the huntingtin (HTT) gene;
5. Evidence of chorea is supported by a Unified Huntington Disease Rating Scale (UHDRS) score ranging from 1 to 4 on any one of chorea items 1 through 7 (*see Appendix D*);
6. If request is for Xenazine, member must use generic tetrabenazine, unless contraindicated or clinically significant adverse effects are experienced;
7. Tetrabenazine is not prescribed concurrently with Austedo<sup>®</sup> or Ingrezza<sup>®</sup>;
8. Dose does not exceed 50 mg per day (*100 mg per day if genotype testing confirms extensive or intermediate CYP2D6 metabolizer status*).

**Approval duration:****Medicaid/HIM** – 6 months**Commercial** – 12 months or duration of request, whichever is less**B. Tardive Dyskinesia (off-label) (must meet all):**

1. Diagnosis of tardive dyskinesia (TD) secondary to treatment with a centrally acting dopamine receptor blocking agent (DRBA) (*see Appendix G*);
2. Prescribed by or in consultation with a psychiatrist or neurologist;
3. Age  $\geq$  18 years;

4. Evidence of moderate to severe TD is supported by an Abnormal Involuntary Movement Scale (AIMS) score of 3 or 4 on any one of items 1 through 9 (*see Appendix H*);
5. If request is for Xenazine, member must use generic tetrabenazine, unless contraindicated or clinically significant adverse effects are experienced;
6. Tetrabenazine is not prescribed concurrently with Austedo or Ingrezza;
7. Dose does not exceed 200 mg per day.

**Approval duration:**

**Medicaid/HIM** – 6 months

**Commercial** – 12 months or duration of request, whichever is less

**C. Other diagnoses/indications** (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. All Indications in Section I** (must meet all):

1. Member meets one of the following (a or b):
  - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
  - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member meets one of the following (a or b):
  - a. For Huntington disease: Member is responding positively to therapy as evidenced by a reduction since baseline in any one of UHDRS chorea items 1 through 7 (*see Appendix D*);
  - b. For TD: Member is responding positively to therapy as evidenced by a reduction since baseline in any one of AIMS items 1 through 9 (*see Appendix H*);
3. If request is for Xenazine, member must use generic tetrabenazine, unless contraindicated or clinically significant adverse effects are experienced;
4. Tetrabenazine is not prescribed concurrently with Austedo or Ingrezza;

5. Request meets one of the following (a or b):
  - a. For Huntington disease: If request is for a dose increase, new dose does not exceed 50 mg per day (*100 mg per day if genotype testing confirms extensive or intermediate CYP2D6 metabolizer status*);
  - b. For TD: If request is for a dose increase, new dose does not exceed 200 mg per day.

**Approval duration:**

**Medicaid/HIM** – 12 months

**Commercial** – 12 months or duration of request, whichever is less

**B. Other diagnoses/indications** (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

AIMS: Abnormal Involuntary Movement Scale

AAN: American Academy of Neurology

DRBA: dopamine receptor blocking agent

FDA: Food and Drug Administration

APA: American Psychiatric Association

HTT: huntingtin

MAOI: monoamine oxidase inhibitors

TD: tardive dyskinesia

UHDRS: Unified Huntington Disease Rating Scale

VMAT2: vesicular monoamine transporter

*Appendix B: Therapeutic Alternatives*

Not applicable

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s):
  - Actively suicidal, or who have depression which is untreated or undertreated
  - Hepatic impairment
  - Taking monoamine oxidase inhibitors (MAOIs) or reserpine
  - Taking deutetabenazine or valbenazine
- Boxed warning(s):
  - Depression and suicidality

*Appendix D: The Unified Huntington Disease Rating Scale (UHDRS)*

- The UHDRS encompasses motor, behavioral, cognitive, and functional components for use in evaluating patients with Huntington disease and is commonly used in both research and clinical practice.
- The American Academy of Neurology (AAN) guidelines evaluating pharmacologic therapies for chorea associated with Huntington disease describe the chorea subscore of the UHDRS motor component as a rating of 7 body regions (facial, bucco-oral-lingual, trunk, extremities) on a five-point scale from 0 to 4 with 0 representing no chorea.
- See Huntington Study Group 1996 and Mestre et al. 2018 for additional information about the UHDRS.

(AAN Guidelines 2012, Huntington Study Group 1996, Mestre 2018)

*Appendix E: Tardive Dyskinesia: General Information*

- Medication-induced movement disorders, including tardive dyskinesia, are organized in the DSM V as follows: neuroleptic-induced parkinsonism/other medication-induced parkinsonism, neuroleptic malignant syndrome, medication-induced acute dystonia, medication-induced acute akathisia, tardive dyskinesia, tardive dystonia/tardive akathisia, medication-induced postural tremor, other medication-induced movement disorder, antidepressant discontinuation syndrome, and other adverse effects of medication.
- Tardive dyskinesia is a type of movement disorder that occurs secondary to therapy with *centrally acting DRBAs* (see Appendix F). (DSM V)
- Typical therapeutic drug classes containing DRBAs include first- and second-generation antipsychotics, antiemetics, and tri-cyclic antidepressants (see Appendix G). (DSM V)
- Other therapeutic drug classes containing agents that have been variously associated with movement disorders are listed below: (Waln 2013, Meyer 2014, Lerner 2015)
  - Antiarrhythmics
  - Antibiotics
  - Anticholinergics
  - Antidepressants
  - Antiepileptics
  - Antihistamines
  - Antimanics
  - Bronchodilators
  - Calcium channel blockers
  - Central nervous system stimulants
  - Dopamine agonists
  - Dopamine depleting agents
  - Dopaminergics
  - Glucocorticoids
  - Immunosuppressants
  - Mood stabilizers
  - Muscle relaxants
  - Oral contraceptives

*Appendix F: Tardive Dyskinesia: DSM-V Definition*

| <b>Tardive Dyskinesia (ICD-9 333.85/ICD-10 G24.01)</b>  |
|---|
| <ul style="list-style-type: none"> <li>• Involuntary athetoid or choreiform movements (lasting at least a few weeks) generally of the tongue, lower face and jaw, and extremities (but sometimes involving the pharyngeal, diaphragmatic, or trunk muscles) developing in association with the use of a neuroleptic medication for at least a few months.</li> <li>• Symptoms may develop after a shorter period of medication use in older persons. In some patients, movements of this type may appear after discontinuation, or after change or reduction in dosage, of neuroleptic medications, in which case the condition is called neuroleptic withdrawal emergent dyskinesia. Because withdrawal emergent dyskinesia is usually time limited, lasting less than 4-8 weeks, dyskinesia that persists beyond this window is considered to be tardive dyskinesia.</li> </ul> |

(DSM V)

*Appendix G: Tardive Dyskinesia: Centrally Acting Dopamine Receptor Blocking Agents (Neuroleptics)*

| Pharmacologic Class     | Therapeutic Class  |   |                            |
|-------------------------|--|---|----------------------------|
|                         | First-generation (typical) antipsychotics  | Antiemetic agents   | Tri-cyclic antidepressants |
| Phenothiazine           | Chlorpromazine<br>Fluphenazine<br>Perphenazine<br>Thioridazine<br>Thiothixene<br>Trifluoperazine | Chlorpromazine<br>Perphenazine<br>Prochlorperazine<br>Promethazine*<br>Thiethylperazine | Amoxapine <sup>†</sup>     |
| Butyrophenone           | Haloperidol  | Droperidol<br>Haloperidol**   |                            |
| Substituted benzamide   |  | Metoclopramide<br>Trimethobenzamide   |                            |
| Dibenzazepine           | Loxapine   |   |                            |
| Diphenylbutylpiperidine | Pimozide   |   |                            |
| Pharmacologic Class     | Second-generation (atypical) antipsychotics  |   |                            |
| Quinolone               | Aripiprazole, brexpiprazole  |   |                            |
| Dibenzazepine           | Asenapine  |   |                            |
| Piperazine              | Cariprazine  |   |                            |
| Dibenzodiazepine        | Clozapine, quetiapine  |   |                            |
| Benzisoxazole           | Iloperidone  |   |                            |
| Benzisothiazole         | Lurasidone, ziprasidone  |   |                            |
| Thienobenzodiazepine    | Olanzapine   |   |                            |
| Pyrimidinone            | Paliperidone, risperidone  |   |                            |

(DSM V, Meyer 2014, Smith 2010, Clinical Pharmacology, Lexicomp)

\*First generation H1 antagonist

\*\*Off-label use

<sup>†</sup>A dibenzoxapine that shares properties with phenothiazines

*Appendix H: Tardive Dyskinesia: The Abnormal Involuntary Movement Scale (AIMS) & APA 2020 Practice Guideline for the Treatment of Patients With Schizophrenia*

- The AIMS is a clinician-rated 12-item assessment tool developed by the National Institute of Mental Health to evaluate severity of involuntary movements in multiple movement disorders including TD. The AIMS is commonly used in both research and clinical practice.
- AIMS items 1-10 are rated on a 5-point scale (0 - none; 1 - minimal; 2 - mild; 3 - moderate; 4 - severe). Items 1-7 assess dyskinesia severity by body region (items 1-4 orofacial; items 5-7 extremity and trunk). Items 8-10 assess overall severity, incapacitation, and patient awareness respectively - item 8 uses the highest score of any one of items 1-7. Items 11 (dental) and 12 (dentures) are yes/no questions which help characterize lip, jaw, and tongue movements.
- See Munetz 1988 for additional information about the AIMS.
- The 2020 American Psychiatric Association (APA) Practice Guideline for the Treatment of Patients With Schizophrenia recommends that patients who have moderate to severe or disabling TD be treated with a reversible VMAT2 inhibitor (i.e., deutetrabenazine, tetrabenazine, and valbenazine); the guideline notes that the AIMS tool can be instrumental in such decision-making.
  - Per the 2020 APA Guideline, tetrabenazine typical dosing range is 25-75 mg per day with the following additional comments: Give in divided doses - increase from initial dose of 25-50 mg/day by 12.5 mg/week to maximum of 150-200 mg/day. Retitrate dose for treatment interruptions of more than 5 days. Test for CYP2D6 metabolizer status before giving doses > 50 mg/day. Do not exceed 50 mg/day in poor metabolizers or in patients treated with a strong inhibitor of CYP2D6.

**V. Dosage and Administration**

| Indication                                  | Dosing Regimen   | Maximum Dose  |
|---|--|---|
| Chorea associated with Huntington's disease | 12.5 mg PO QD for first week, then 12.5 mg PO BID for second week, then titrate by 12.5 mg weekly thereafter to tolerated dose that reduces chorea; doses of 37.5 mg and up to 50 mg/day should be administered in 3 divided doses per day | 50 mg/day (max single dose of 25 mg)<br><br>Extensive or intermediate CYP2D6 metabolizer: 100 mg/day (max single dose of 37.5 mg) |
| TD ( <i>off-label</i> )*                    | Typical dosing range 25-75 mg/day.<br>Give in divided doses: increase from initial dose of 25-50 mg/day by 12.5 mg/week to maximum of 150-200 mg/day.<br>Test for CYP2D6 metabolizer status before giving doses > 50 mg/day                | 150-200 mg/day  |

*\*Off-label dose supported by the 2020 American Psychiatric Association (APA) Practice Guideline for the Treatment of Patients With Schizophrenia. See additional dosing comments in Appendix H.*

**VI. Product Availability**

Tablets: 12.5 mg, 25 mg

## VII. References

1. Xenazine Prescribing Information. Deerfield, IL: Lundbeck; November 2019. Available at: <http://www.xenazineusa.com/>. Accessed February 5, 2023.

### Huntington Disease

2. Potter NT, Spector EB, Prior TW. Technical standards and guidelines for Huntington disease testing. *Genet Med*. 2004;6(1):61-65.
3. Bean L and Bayrak-Toydemir R. American College of Medical Genetics and Genomics Standards and Guidelines for Clinical Genetics Laboratories, 2014 edition: technical standards and guidelines for Huntington disease. *Genet Med*. 2014 Dec;16(12):e2.
4. Bean L, Bayrak-Toydemir P, ACMG Laboratory Quality Assurance Committee. Addendum: American College of Medical Genetics and Genomics Standards and Guidelines for Clinical Genetics Laboratories, 2014 edition: technical standards and guidelines for Huntington disease. *Genet Med*. 2021;23(12):2461.
5. Kremer B, Goldberg P, Andrew SE. A worldwide study of the Huntington's disease mutation: the sensitivity and specificity of measure CAG repeats. *NEJM*. May 19, 1994; 330(20):1401-1406.
6. Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. August 7, 2012;79:598-603.
7. Unified Huntington's disease rating scale: reliability and consistency. Movement Disorder Society. *Movement Disorders*. 1996;11(2):136-143.
8. Mestre TA, Forjaz MJ, Mahlknecht P, et al. Rating scales for motor symptoms and signs in Huntington's disease: Critique and recommendation. *International Parkinson and Movement Disorders Society. Movement Disorders Clinical Practice*. 2018;5(2):111-117. DOI:10.1002/mdc3.1257.

### Tardive Dyskinesia

9. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. 2020. Third Ed. Available at: <https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines>.
10. Munetz MR, Sheldon B. How to examine patients using the abnormal involuntary movement scale. *Hospital and Community Psychiatry*. November 1988;39(11):1172-77.
11. Bhidayasiri R, Jitkriksadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. *Journal of the Neurological Sciences*. 2018;389:67-75.
12. Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes. Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2013;31:463-469.
13. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. *Tremor Other Hyperkinet Mov (N Y)*. July 12, 2013;3:tre-03-161-4138-1. DOI:10.7916/D88P5Z71. Print 2013.
14. Witter DP, Holbert RC, Suryadevara U. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients. *Expert Opin Pharmacother*. April 26, 2017. DOI:10.1080/14656566.2017.1323874. [Epub ahead of print.]
15. Meyer TA, Belson TE, McAllister R. Tardive dyskinesia: a distressing drug-induced movement disorder. *US Pharm*. 2014;39(1):HS13-HS16.

16. Lerner PP, Miodownik C, Lerner V. Tardive dyskinesia (syndrome): current concept and modern approaches to its management. *Psychiatry Clin Neurosci*. June 2015;69(6):321-34.
17. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. *Alimentary Pharmacology and Therapeutics*. January 2010;31(1):11-19.
18. Smith HS, Cox LR, Smith BR. Dopamine receptor antagonists. *Annals of Palliative Medicine*. July 2012;1(2). DOI: 10.3978/j.issn.2224-5820.2012.07.09.

| Reviews, Revisions, and Approvals   | Date     | P&T Approval Date |
|---|----------|-------------------|
| 2Q 2019 annual review: no significant changes; references reviewed and updated.   | 02.26.19 | 05.19             |
| 2Q 2020 annual review: no significant changes; references reviewed and updated.   | 02.11.20 | 05.20             |
| Genetic testing and UHDRS scoring added to chorea criteria; Appendix D added; references reviewed and updated.  | 07.07.20 | 08.20             |
| 2Q 2021 annual review: added off-label indication of TD supported by APA 2020 Practice Guideline and relevant appendices E, F, G, and H for supporting information; Commercial line of business added; references for HIM line of business off-label use revised from HIM.PHAR.21 to HIM.PA.154; references reviewed and updated. | 02.16.21 | 05.21             |
| Revised approval duration for Commercial line of business from length of benefit to 12 months or duration of request, whichever is less.  | 09.27.21 | 02.22             |
| 2Q 2022 annual review: no significant changes; references reviewed and updated.   | 01.24.22 | 05.22             |
| Per May SDC and prior clinical guidance, added redirection for both initial and continuation of therapy to require redirection to generic tetrabenazine.  | 05.20.22 | 08.22             |
| Template changes applied to other diagnoses/indications and continued therapy section.  | 10.12.22 |                   |
| 2Q 2023 annual review: no significant changes; references reviewed and updated.   | 02.05.23 | 05.23             |

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.



The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note: For Medicaid members,** when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2011 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright

or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.